Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report released on Saturday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Aethlon Medical in a research note on Friday.

Aethlon Medical Stock Performance

Shares of NASDAQ:AEMD opened at $0.40 on Friday. The stock’s 50-day moving average price is $0.40 and its two-hundred day moving average price is $0.49. Aethlon Medical has a 12-month low of $0.24 and a 12-month high of $2.35. The firm has a market cap of $5.57 million, a price-to-earnings ratio of -0.14 and a beta of 1.74.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.10. During the same period in the prior year, the company posted ($1.30) EPS. As a group, research analysts forecast that Aethlon Medical will post -1.1 earnings per share for the current fiscal year.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.